Page 7 - Exscientia News Today

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: Morgan Stanley EMEA HealthTech Conference. Management

- EXS4318 is the first immunology inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - Exscientia invented a potentially first-in-class potent and selective

Uses multi-omics to identify a biomarker which could be predictive of '546 response in the clinic Differentiated '546 development and patient enrichment strategy driven by Exscientia's precision

- Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC - - Exscientia's A2A biomarker signature for patient selection will be prospectively tested during the trial

Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT 8:30 a.m. EST Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30

Fast and accurate generative AI design of novel antibodies extends Exscientia's capabilities beyond small molecules Sequencing paired human antibody data to create better AI models for antibody

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 2022 A.I. and Disruptive

Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific

Findings support deep learning ex vivo drug screening with patient tissue as a promising tool to identify effective, individual treatments in advanced blood cancer over conventional methods Custom

Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia's People (human resources) and